The breakthroughs achieved in the rapid and cost-effective analysis of the human genome have illuminated the path towards uncovering the underlying causes of rare disorders. Families, who have endured years of what can only be described as diagnostic odysseys, have now found hope. They have transitioned from one specialist to another in their quest to unravel the mysteries of their loved one’s rare ailment. Genomic testing has emerged as a beacon of relief for these individuals and their families, while also fostering connections among similarly affected families, allowing them to share their journeys and challenges.

DelveInsight has recently released a series of epidemiology-based market reports focusing on rare genetic disorders including Hereditary Angioedema, Wilson Disease, Menkes Disease, and Alpha-1 Antitrypsin Deficiency (AA1TD). These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2019 to 2032  segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Additionally, the reports feature exhaustive analyses of prominent companies working with their emerging candidates in different stages of clinical development. Let’s deep dive into the assessment of these rare genetic disorder markets individually.